DAVID FLOCKHART, board member of The Personalized Medicine Coalition, died Nov. 26.
CITY of HOPE announced three recent hires.
MD Anderson Cancer Center and Boehringer Ingelheim announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma.
Johnson & Johnson officials said the company was unaware of any reportable adverse events resulting from the use of power morcellators prior to 2013.
FDA officials said the agency didn't receive any reports of adverse outcomes resulting from power morcellation prior to December 2013.
Congressional Panel Chair Questions Whether J&J, Brigham Reported Morcellation Adverse Events to FDA
The House Committee on Energy & Commerce has stepped into a key role in the controversy over power morcellation.
The text of Hooman Noorchashm's Nov. 13 letter to the editor of The Cancer Letter follows. Noorchashm is an assistant professor and cardiac surgeon at Thomas Jefferson University Hospital.
The text of Amy Reed's Nov. 13 letter to Ron Walls, executive vice president and chief operating officer at Brigham & Women's Hospital, follows. Reed is an assistant professor of anesthesia and critical care medicine at the Hospital of the University of Pennsylvania.
The text of Ron Walls's Nov. 10 response to Rep. Mike Fitzpatrick's (R-Pa.) letter follows. Walls is executive vice president and chief operating officer at Brigham & Women's Hospital.
The text of Rep. Mike Fitzpatrick's Nov. 5 letter to Ron Walls, executive vice president and chief operating officer at Brigham & Women's Hospital, follows: